Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Royalty Pharma Plc Cl A (NQ: RPRX ) 28.21 +0.02 (+0.07%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,609,897 Open 28.26 Bid (Size) 28.10 (2) Ask (Size) 28.57 (1) Prev. Close 28.19 Today's Range 28.18 - 28.50 52wk Range 25.20 - 31.66 Shares Outstanding 388,132,400 Dividend Yield 2.84% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 10 Health Care Stocks With Whale Alerts In Today's Session September 18, 2024 Via Benzinga 3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade September 16, 2024 Now could be a great time to scoop up three stocks trading way below their previous peaks. Via The Motley Fool Performance YTD -0.21% -0.21% 1 Month -1.09% -1.09% 3 Month +5.77% +5.77% 6 Month -7.11% -7.11% 1 Year +5.66% +5.66% More News Read More 2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 September 08, 2024 Via The Motley Fool Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut September 04, 2024 Via Benzinga Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement September 03, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference August 28, 2024 From Royalty Pharma plc Via GlobeNewswire Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation' August 16, 2024 Via Benzinga RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 Via InvestorPlace Royalty Pharma Reports Second Quarter 2024 Results August 08, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital July 24, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 July 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Third Quarter 2024 Dividend July 17, 2024 From Royalty Pharma plc Via GlobeNewswire Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? July 11, 2024 Via Investor's Business Daily Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 June 26, 2024 Via InvestorPlace 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 Via InvestorPlace Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields June 12, 2024 Via Benzinga June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge June 05, 2024 Via InvestorPlace Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes June 03, 2024 From Royalty Pharma plc Via GlobeNewswire Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? May 28, 2024 Via Benzinga Exposures Product Safety Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out May 28, 2024 Via Investor's Business Daily Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million May 28, 2024 From Royalty Pharma plc Via GlobeNewswire Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe May 23, 2024 Via Benzinga Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline May 22, 2024 From Royalty Pharma plc; Cytokinetics Via GlobeNewswire 7 Dividend Stocks to Buy at a 52-Week Low May 20, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
